Vascular Biogenics (VBLT) News Today → The only financial event in 2024 that matters (From Porter & Company) (Ad) Free VBLT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | msn.comVBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To ComeNovember 3, 2023 | msn.comVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26October 16, 2023 | finance.yahoo.comNotable Labs Closes Merger Transaction With VBL TherapeuticsOctober 12, 2023 | finance.yahoo.comVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingOctober 4, 2023 | finance.yahoo.comVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingSeptember 9, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeSeptember 6, 2023 | finance.yahoo.comVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 14, 2023 | finance.yahoo.comVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 23, 2023 | fool.comVascular Biogenics (NASDAQ: VBLT)May 15, 2023 | finance.yahoo.comVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 4, 2023 | benzinga.comVascular Biogenics Stock (NASDAQ:VBLT), DividendsMarch 17, 2023 | finance.yahoo.comVascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)March 14, 2023 | finance.yahoo.comVBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comVBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in CashFebruary 27, 2023 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLTFebruary 23, 2023 | technews.tmcnet.comVBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to ShareholdersFebruary 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. MergerFebruary 23, 2023 | marketwatch.comVascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLTFebruary 23, 2023 | msn.comVascular Biogenics rises 85% on all-stock merger deal with Notable LabsFebruary 23, 2023 | investorplace.comWhy Is Vascular Biogenics (VBLT) Stock Up 52%?February 23, 2023 | marketbeat.comTrading was temporarily halted for "VBLT" at 06:02 AM with a stated reason of "News pending."February 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in CashNovember 10, 2022 | finance.yahoo.comOYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue EstimatesSeptember 2, 2022 | finance.yahoo.comAxsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07September 1, 2022 | finance.yahoo.comVBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencySeptember 1, 2022 | finance.yahoo.comSorrento (SRNE) Gets FDA Fast Track Tag for Back Pain ProductAugust 2, 2022 | marketwatch.comVascular Biogenics Cutting About 35% of Staff >VBLTAugust 2, 2022 | finance.yahoo.comVBL Therapeutics Announces Workforce ReductionJuly 21, 2022 | finance.yahoo.comVascular Biogenics (VBLT) Down, Ovarian Cancer Study FailsJuly 20, 2022 | msn.comGold Prices Settle Lower; Vascular Biogenics Shares PlummetJuly 20, 2022 | msn.comWhy Is Vascular Biogenics (VBLT) Stock Down 80% Today?July 20, 2022 | finance.yahoo.comRead Why VBL Therapeutics Shares Are Falling To a 52-Week LowJuly 19, 2022 | finance.yahoo.comVBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian CancerJuly 19, 2022 | marketbeat.comTrading was temporarily halted for "VBLT" at 04:07 PM with a stated reason of "News pending."July 18, 2022 | marketbeat.comVascular Biogenics (NASDAQ:VBLT) Given "Outperform" Rating at OppenheimerOppenheimer reissued an "outperform" rating and set a $5.50 price objective on shares of Vascular Biogenics in a report on Monday.July 4, 2022 | marketbeat.comShort Interest in Vascular Biogenics Ltd. (NASDAQ:VBLT) Declines By 22.4%Vascular Biogenics Ltd. (NASDAQ:VBLT - Get Rating) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 328,700 shares, a decline of 22.4% from the May 31st total of 423,700 shares. Based on an average daily volume of 163,400 shares, the days-to-cover ratio is currently 2.0 days. Currently, 0.7% of the shares of the stock are sold short.June 10, 2022 | marketbeat.comVascular Biogenics (NASDAQ:VBLT) Upgraded by Zacks Investment Research to HoldZacks Investment Research raised shares of Vascular Biogenics from a "sell" rating to a "hold" rating in a research note on Friday.May 31, 2022 | finance.yahoo.comVBL Therapeutics to Participate in the Jefferies Healthcare ConferenceMay 20, 2022 | marketbeat.comQ2 2022 EPS Estimates for Vascular Biogenics Ltd. (NASDAQ:VBLT) Decreased by OppenheimerVascular Biogenics Ltd. (NASDAQ:VBLT - Get Rating) - Equities research analysts at Oppenheimer lowered their Q2 2022 EPS estimates for Vascular Biogenics in a report issued on Tuesday, May 17th. Oppenheimer analyst K. Degeeter now forecasts that the biopharmaceutical company will post earnings ofMay 19, 2022 | marketbeat.comOppenheimer Comments on Vascular Biogenics Ltd.'s Q1 2023 Earnings (NASDAQ:VBLT)Vascular Biogenics Ltd. (NASDAQ:VBLT - Get Rating) - Equities researchers at Oppenheimer issued their Q1 2023 earnings per share (EPS) estimates for shares of Vascular Biogenics in a report issued on Tuesday, May 17th. Oppenheimer analyst K. Degeeter expects that the biopharmaceutical company wilMay 17, 2022 | stockhouse.comVBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 10, 2022 | finance.yahoo.comVBL Therapeutics to Report First Quarter 2022 Financial Results on May 17May 8, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In Vascular Biogenics Ltd.'s (NASDAQ:VBLT) Shares?May 3, 2022 | finance.yahoo.comVBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in MayApril 28, 2022 | marketbeat.comVascular Biogenics (NASDAQ:VBLT) Now Covered by Analysts at Chardan CapitalChardan Capital assumed coverage on Vascular Biogenics in a research report on Thursday. They set a "buy" rating and a $5.00 target price on the stock.April 26, 2022 | msn.comThe Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell ...April 16, 2022 | seekingalpha.comVascular Biogenics (VBLT) Presents at the KOL Event on Ovarian Cancer - SlideshowMarch 29, 2022 | marketbeat.comZacks Investment Research Lowers Vascular Biogenics (NASDAQ:VBLT) to SellZacks Investment Research cut Vascular Biogenics from a "hold" rating to a "sell" rating in a report on Tuesday. Get Vascular Biogenics News Delivered to You Automatically Sign up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” VBLT Media Mentions By Week VBLT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VBLT News Sentiment▼0.000.76▲Average Medical News Sentiment VBLT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VBLT Articles This Week▼00▲VBLT Articles Average Week Get Vascular Biogenics News Delivered to You Automatically Sign up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NAMS News EVO News KURA News TARO News EWTX News SDGR News ARDX News LGND News MORF News AVDL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VBLT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsLEAKED: Jeff Bezos' $330 Million GambleBehind the MarketsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vascular Biogenics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
